Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Shares of Novo Nordisk, the Danish pharmaceutical company ... which is being marketed under its brand name CagriSema. According to the results, the once-a-day pill improved blood sugar levels ...

BMO Capital Markets analyst Evan David Seigerman downgraded Novo Nordisk NVO from Outperform to Market Perform, lowering the price forecast from $105 to $64. Per Seigerman, Novo Nordisk’s stock may ...